Benjamin Halladay - 13 Mar 2026 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Financial Officer
Signature
/s/ Sheldon L. Koenig, by power of attorney
Issuer symbol
ESPR
Transactions as of
13 Mar 2026
Net transactions value
$0
Form type
4
Filing time
16 Mar 2026, 16:19:29 UTC
Previous filing
18 Dec 2025
Next filing
18 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Halladay Benjamin Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR /s/ Sheldon L. Koenig, by power of attorney 16 Mar 2026 0001953943

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award +247,430 +52% $0.000000* 720,026 13 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ESPR Stock Option (right to buy) Award +221,270 $0.000000* 221,270 13 Mar 2026 Common Stock 221,270 $2.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.
F2 Includes 5,071 shares recently acquired in Esperion's Employee Stock Purchase Plan.